Meeting
2017 ASCO Annual Meeting
The scope of possible combination therapy with immunotherapy and targeted therapy.
Authors
Leandro Machado Colli
National Cancer Institute, National Institutes of Health, Rockville, MD
Leandro Machado Colli , Mitchell J Machiela , Han Zhang , Timothy A Myers , Lea Jessop , Olivier Delattre , Kai Yu , Stephen J. Chanock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research,Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3056)
DOI
10.1200/JCO.2017.35.15_suppl.3056
Abstract #
3056
Poster Bd #
151
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock
Poster
2014 ASCO Annual Meeting
Impact of next-generation sequencing (NGS) on treatment decisions in the community oncology setting.
First Author: Lindsay Carol Overton
Poster
2016 ASCO Annual Meeting
NCI-MATCH (Molecular Analysis for Therapy Choice) – a national signal finding trial.
First Author: Barbara A. Conley
Poster
2015 ASCO Annual Meeting
Comprehensive genomic profiling of clinically advanced colorectal carcinoma to reveal frequent opportunities for targeted therapies.
First Author: Jeffrey S. Ross